By itself, the US Food and Drug Administration’s approval of Tibsovo (ivosidenib) for IDH1-mutated cholangiocarcinoma is a largely incremental development for a drug already on the market for three years. But for Servier Pharmaceuticals, it marks its entry into solid tumors and an important step for a larger oncology strategy that is particularly focused on hot-topic disease targets and modalities like immune checkpoint inhibitors, biomarker-driven indications and cell therapy.
The Boston-based company, part of France-based Les Laboratoires Servier SAS, announced Tibsovo’s approval on 25 August in adults with...